First Ascent Biomedical in the News
First Ascent Biomedical in the News
The interview explores First Ascent Biomedical’s mission to bring personalized cancer care to patients. Through [...]
http://AI-Driven Platform Aims to Bring Personalized Cancer Treatment to More Patients | Clinical Lab Products
The interview highlights how First Ascent Biomedical is pioneering personalized treatments for pediatric cancer. By [...]
This September—National Childhood Cancer Awareness Month—we’re reminded that while progress has been made, the fight is [...]
This is a TEDx presentation delivered by First Ascent’s co-founder, Dr. Diana Azzam, illustrating the [...]
https://reachmd.com/programs/project-oncology/personalized-oncology-in-action-advancing-care-with-functional-precision-medicine/36494/
https://reachmd.com/news/innovation-in-cancer-care-a-focus-on-patient-centered-solutions-and-research-acceleration/2475479/
First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional [...]
Dr. Diana Azzam, Co-Founder of First Ascent Biomedical and Associate Professor at Florida International University [...]
ERIE, Pa. (March 26, 2025) -- Gannon University, Saint Vincent Hospital and First Ascent Biomedical [...]
First Ascent Biomedical Awarded Florida Cancer Innovation Fund Grant Grant Focused on Advancing Precision Cancer [...]
CancerX is a groundbreaking public-private partnership designed to accelerate innovation in the fight against cancer. [...]
This is the first time Nature Medicine published a Functional Precision Medicine approach for treating [...]
Our study shows the technical feasibility of integrating functional precision medicine approaches for patients with [...]
Our studies demonstrate the potential for predictive and generative artificial intelligence and machine learning approaches [...]
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its [...]
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex [...]
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and [...]
Groundbreaking findings published in Nature Medicine shows improved outcomes when standard treatments fail Miami, [...]
Function Precision Medicine (FPM) and AI to provide new treatment options for minority childhood cancer [...]
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Read [...]
Systemic therapy for metastatic clear cell sarcoma (CCS) bearing EWSR1-CREB1/ATF1 fusions remains an unmet clinical [...]
Over the past 25 years, chemotherapy regimens for osteosarcoma have failed to improve the 65-70% [...]
Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young [...]
The collaboration between Lucem Health, Mayo Clinic Platform, and First Ascent Biomedical will reduce complexity [...]
Moving drugs to and through phased trials, especially in cancer, is daunting and riddled with [...]
orrectly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the [...]
Correctly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the [...]
Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective [...]
Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms [...]
As high-throughput sequencing experiments become more widely used in pre-clinical and clinical settings, pharmacogenetic and [...]
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients [...]
Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a [...]
Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric cancer with unmet clinical need. DIPG [...]
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood with a propensity to metastasize. [...]
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of [...]
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of [...]
In this case report we evaluate the genetics of and scientific basis of therapeutic options [...]
Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft [...]
Rhabdomyosarcoma (RMS) is the most common childhood soft-tissue sarcoma. The largest subtype of RMS is [...]
CIC-rearranged sarcomas (CRSs) have recently been characterized as a distinct sarcoma subgroup with a less [...]
Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. Read [...]
Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine [...]
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. [...]
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival [...]
Feline injection-site sarcoma (FISS), an aggressive iatrogenic subcutaneous malignancy, is challenging to manage clinically and [...]
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical [...]
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal childhood cancer of the brain. Despite [...]
In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell [...]
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic [...]
Publication and Pharma Partners
